Cyclic nucleotide phosphodiesterases (PDEs): Diverse regulators of cyclic nucleotide signals and inviting molecular targets for novel therapeutic agents

Thrombosis and Haemostasis

Volumn 82, Issue 2, 1999, Pages 407-411

  Manganiello, V C ^a   Degerman, E ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOBUTYL 8 METHOXYMETHYL 1 METHYLXANTHINE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; CILOSTAZOL; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; METHYLXANTHINE; MILRINONE; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; SILDENAFIL; THEOPHYLLINE; ZAPRINAST;

CONFERENCE PAPER; DRUG TARGETING; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; GENE STRUCTURE; HUMAN; INTERMITTENT CLAUDICATION; MULTIGENE FAMILY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0032723853     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615860     Document Type: Conference Paper

References (40)

1. Beavo J, Conti M, Heaslip RJ. Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol. 1994;46:399-405.
2. Torphy T. Phosphodiesterase isoenzymes: molecular targets for novel anti-asthma agents. Am J Respir Crit Care Med. 1998;157:351-370.
3. Dousa T. Cyclic-3'5'-Nucleotide phosphodiesterase isoenzymes in cell biology and pathophysiology of the kidney. Kidney Int. 1999;55:29-62.
4. Degerman E, Belfrage P, Manganiello VC. Structure, localization and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem. 1997;272:6823-6826.
5. Perry M, Higgs G. Chemotherapeutic potential of phosphodiesterase inhibitors. Curr Opin Chem Biol. 1998;2:472-481.
6. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75:725-748.
7. Soderling SH, Bayuga SJ, Beavo JA. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem. 1998;273:15553-15558.
8. Fisher DA, Smith JF, Pillai JS, St. Dennis SH, Cheng J. Isolation and characterization of PDE9A, a novel cGMP-specific phosphodiesterase. J Biol Chem. 1998;273:15559-15564.
9. Houslay MD, Milligan G. Tailoring cAMP-signaling responses through isoform multiplicity. TIBS. 1997;22:217-224.
10. Chini C, Grande J, Chini E, Dousa, TP. Compartmentalization of cAMP signaling by phosphodiesterase isoenzymes PDE3 and PDE4: regulation of superoxidation and mitogenesis. J Biol Chem. 1997;272:9854-9859.
11. Gillespie PG. Phosphodiesterases in visual transduction in rods and cones. In: Beavo JA, Houslay MD, ed. Phosphodiesterases: Structure, Regulation and Drug Action, John Wiley and Sons, Inc., New York; 1990:163-184.
12. McLaughlin ME, Ehrhart TL, Berson EL, Dryja TP. Mutation spectrum of the gene encoding the β subunit of rod phosphodiesterase among patients with recessive retinitis pigmentosa. Proc Natl Acad Sci USA. 1995;92:3249-3253.
13. MacFarland RT, Zelus BD, Beavo JA. High concentrations of a cGMP-stimulated PDE mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa. J Biol Chem. 1991;266:136-142.
14. Dickinson N, Jang EK, Haslam RJ. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation. Biochem J. 1997;323:371-377.
15. Ahmad F, Gao G, Wang L-M, Lanstrom TR, Degerman E, Pierce JH, Manganiello VC. IL-3 and IL-4 activate cyclic nucleotide phosphodiesterases 3 (PDE3) and 4 (PDE4) by different medianisms in FDCP2 myeloid cells. J Immunol. 1999;162:4864-4875.
16. Conti M, Nemoz G, Sette C, Vicini E. Recent progress in understanding hormonal regulation of phosphodiesterases. Endocr Rev. 1995;16:370-389.
17. Zhao A, Bornfeldt K, Beavo JA. Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. J Clin Invest. 1998;5:869-873.
18. Tsafriri A, Chun SY, Zhang R, Hsush AJW, Conti M. Oocyte maturation involves compartmentalization and opposing changes in cAMP levels in follicular somatic and germ cells - studies using selective phosphodiesterase inhibitors. Dev. Biol. 1996;178:393-402.
19. Wijkander J, Landstrom TR, Manganiello VC, Belfrage P, Degerman E. Insulin-induced phosphorylation and activation of phosphodiesterase 3B in rat adipocytes: possible role for protein kinase B but not mitogen-activated protein kinase or p70S6 kinase. Endocrinology. 1998;139:219-227.
20. Pyne N, Cooper M, Houslay M. The insulin- and glucogen-stimulated "dense vesicle" high affinity cAMP phosphodiesterase from rat liver. Biochem J. 1987;242:33-42.
21. Andersen C, Roth R, Conti M. Protein kinase B/Akt induces resumption of meiosis in Xenopus oocytes. J Biol Chem. 1998;273:31515-31525.
22. Rybalkin SD, Bornfeldt K, Sonnenberg WK, Rybalkin IG, Kwak KS, Hanson K, Krebs EG, Beavo, JA. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic proliferative phenotype. J Clin Invest. 1996;100:2611-2621.
23. Komas N, Movsesian M, Kedev S, Degerman E, Belfrage P, Manganiello VC. cGMP-inhibited phosphodiesterases. In: Schudt C, Dent G, Rabe KF, eds. Phosphodiesterase Inhibitors, Academic Press, New York; 1996:89-109.
24. Souness JH, Hassall GA, Parrott DP. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem Pharmacol. 1992;44:857-866.
25. Pan X, Arauz E, Krzanowski JJ, Fitzpatrick DF, Polson JE. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isoenzyme families PDEIII and PDEIV to attenuate proliferation of rat vascular smooth muscle cells. Biochem Pharmacol. 1994;48:827-835.
26. Johnson-Mills K, Arauz E, Coffey RG, Krzanowski JJ, Polson JB. Effects of CI-930 and Rolipram on human coronary artery smooth muscle cell proliferation. Biochem Pharmacol. 1998;56:1065-1073.
27. + T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol. 1966;118:1945-1948.
28. Robicsek S, Blanchard D, Djeu J, Krzanowski J, Szentevanyi A, Polson, J. Multiple high affinity cAMP phosphodiesterases in human T-lymphocytes. Biochem Pharmacol. 1991;42:869-877.
29. Marcos P, Prigent A, Lagarde M, Nemoz G. Modulation of rat thymocyte proliferative response through inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents. Mol Pharmacol. 1993;44:1027-1035.
30. Li L, Yee C, Beavo JA. CD3- and CD28-dependent induction of PDE7 required for T-cell activation. Science. 1999;283:848-851.
31. Tenor N, Schudt C. Analysis of PDE isoenyzme profiles in cells and tissues by pharmacological methods. In: Schudt C, Dent G, Rabe KF, eds. Phosphodiesterase Inhibitors, Academic Press, New York; 1996:21-40.
32. Houslay MD, Sullivan M, Bolger GB. The multienzyme PDE4 cAMP-specific PDE family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and anti-depressant actions. Adv Pharmacol. 1998;44:225-342.
33. Silver P. Inhibition of phosphodiesterase isoenzymes and cell function by selective PDE5 inhibitors. In: Schudt C, Dent G, Rabe KF, eds. Phosphodiesterase Inhibitors, Academic Press, New York; 1996:127-134.
34. Cohen AH, Hanson K, Morris K, Fonty B, McMurty I, Clarke W, Rodman D. Inhibition of cGMP-specific phosphodiesterase selective vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest. 1996;97:172-179.
35. Liang L, Beshay E, Prud'homme GJ. The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in mice. Diabetes. 1998;47:570-575.
36. Ross SE, Williams RO, Mason LJ, Mauri C, Marinova-Mutafchieva L, Malfort A-M, Maini R, Feldmann M. Suppression of TNFa expression, inhibition of Th1 activity and amelioration of collagen-induced arthritis by rolipram. J Immunol. 1997;159:6253-6259.
37. Sommer N, Loschmann PA, Northoff GH, Weller M, Steinbrecher A, Steinbach JP, Lichtenfels R, Myermann R, Reithmuller A, Fontana A, Dichgans J, Martin R. The antidepressant Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. Nat Med. 1995;1:244.
38. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. A comparison of oral Milrinone, Digoxin and their combination in treatment of patients with chronic heart failure. New Engl J Med. 1998;320:677-683.
39. Tsuchikane E, Katoh O, Sumitsuji S, Fukuhara A, Funamoto M, Otsuji H, Awata N, Kobayashi T. Impact of Cilostazol on intimal proliferation after directional coronary atherectomy. Am Heart J. 1998;135:495-502.
40. Boolell M, Allen MJ, Ballard SA, Gepi-Altee S, Murhead GJ, Naylor AM, Osterloh IH, Gingell C. Sildenafil, an orally active type 5 cGMP-specific phosphodiesterase inhibitor for the treatment of erectile dysfunction. Int J Impot Res. 1996;8:47-52.